NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Quantum BioPharma's CTV W5 Investigation and Stock Manipulation Allegations
TL;DR
Quantum BioPharma's $700 million lawsuit against CIBC and RBC could expose stock manipulation tactics and potentially recover significant value for shareholders.
Quantum BioPharma alleges illegal stock spoofing tactics in its lawsuit while advancing Lucid-MS, a drug candidate shown to reverse nerve degradation in preclinical studies.
Quantum BioPharma's Lucid-MS drug candidate offers hope for multiple sclerosis patients by potentially halting and reversing nerve-cell degradation to improve quality of life.
CTV's W5 investigative series examines Quantum BioPharma's allegations of market manipulation while highlighting their promising MS drug that reverses nerve damage in animal studies.
Found this article helpful?
Share it with your network and spread the knowledge!
The CTV W5 investigation examines Quantum BioPharma and its allegations of stock market manipulation, specifically focusing on 'stock spoofing' - an illegal trading tactic central to the company's $700 million lawsuit against CIBC and RBC.
Quantum BioPharma's lead compound is Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, which is the underlying mechanism of multiple sclerosis.
Quantum BioPharma has filed a $700 million lawsuit against CIBC and RBC related to alleged stock market manipulation through illegal trading tactics.
Stock spoofing is described as an illegal trading tactic that is central to Quantum BioPharma's allegations of market manipulation in their lawsuit against the banks.
Quantum BioPharma invented unbuzzd™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining 20.11% ownership and royalty payments, plus maintains strategic investments through its subsidiary FSD Strategic Investments Inc. representing property-secured loans.
The three-part W5 investigative series begins airing today, according to the press release content.
CEO Zeeshan Saeed thanked W5 for its reporting and reiterated the company's goal of advancing Lucid-MS, their multiple sclerosis drug candidate.
Quantum BioPharma receives 7% royalty payments from unbuzzd™ sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.
The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM
Quantum BioPharma focuses on treating challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.
Curated from InvestorBrandNetwork (IBN)
